P. Wang et al. / Tetrahedron Letters 51 (2010) 3975–3977
3977
4. Burger’s Medicinal Chemistry and Drug Discovery; Abraham, D. J., Ed.; John Wiley
and Sons: New York, 2003; Vol. 1,.
5. (a) Ismail, F. M. D. J. Fluorine Chem. 2002, 118, 27–33; (b) Welch, J. T.;
Ewarakrishnan, S. E. Fluorine in Bioorganic Chemistry; John Wiley: New York,
1991; (c) Becker, A. Inventory of Industrial Fluoro-Biochemicals; Eyrolles: Paris,
1996.
O
O
O
O
+
ArCHO
1
2
6. (a) Lavilla, R. J. Chem. Soc., Perkin Trans. 1 2002, 1141–1156; (b) Sausins, A.;
Duburs, G. Heterocycles 1988, 27, 269–289.
O
O
Ar
O
O
7. (a) Meguro, K.; Aizawa, M.; Sohda, T.; Kawamatsu, Y.; Nagaoka, A. Chem. Pharm.
Bull. 1985, 33, 3787–3797; (b) Triggle, D. J. Cell. Mol. Neurobiol. 2003, 23, 293–
303; (c) De Simone, R. W.; Currie, K. S.; Mitchell, S. A.; Darrow, J. W.; Pippin, D.
A. Comb. Chem. 2004, 7, 473–493; (d) Loev, B.; Ehrreich, S. J.; Tedeschi, R. E. J.
Pharm. Pharmacol. 1972, 24, 917–918; (e) Harrold, M. In Foye’s Principles of
Medicinal Chemistry; Williams, D. A., Lemke, T. L., Eds., 5th ed.; Lippin-cott
Williams and Wilkins: Baltimore, 2002; pp 533–561; (f) Mojarrad, J. S.; Vo, D.;
Velázquez, C.; Knaus, E. E. Bioorg. Med. Chem. 2005, 13, 4085–4091.
8. (a) Bossert, F.; Meyer, H.; Wehinger, E. Angew. Chem., Int. Ed. 1981, 20, 762–769;
(b) Stout, D. M.; Meyers, A. I. Chem. Rev. 1982, 82, 223–243; (c) Janis, R. A.;
Silver, P. J.; Triggle, D. J. Adv. Drug Res. 1987, 16, 309–591; (d) Bossert, F.; Vater,
W. Med. Res. Rev. 1989, 9, 291–324; (e) Marchalin, S.; Chudik, M.; Mastihuba,
V.; Decroix, B. Heterocycles 1998, 48, 1943–1958; (f) Achiwa, K.; Kato, T. Curr.
Org. Chem. 1999, 3, 77–106.
O
NH4OAc
HOAc
O
O
O
OEt
CF3
+
O
O
F3C
OEt
Ar
O
NH3
O
3
B
A
acetone
Ar
Ar
O
CO2Et
OH
HOOC
-CO2
OEt
OH
C
O
9. (a) Schramm, M.; Thomas, G.; Towan, I. L.; Franckowiak, G. Nature 1983, 303,
535–537; (b) Brown, A. M.; Kunz¢, D. L.; Yatani, A. Nature 1984, 311, 570–572;
(c) Chorvat, R. J.; Rorig, K. J. J. Org. Chem. 1988, 53, 5779–5781; (d) Kappe, C. O.
Tetrahedron 1993, 49, 6937–6963; (e) Kappe, C. O.; Fabian, W. M. F. Tetrahedron
1997, 53, 2803–2816.
O
N
H
CF3
H2N CF3
C
5
Scheme 1. A possible mechanism for formation of 5.
10. (a) Song, L. P.; Li, X. F.; Xing, C. H.; Li, D. M.; Zhu, S. Z.; Deng, H. M.; Shao, M.
Synlett 2010, 5, 830–834; (b) Dai, B. F.; Song, L. P.; Wang, P. Y.; Yi, H.; Jin, G. F.;
Zhu, S. Z.; Shao, M. Synlett 2009, 11, 1842–1846; (c) Song, S. D.; Song, L. P.; Dai,
B. F.; Yi, H.; Jin, G. F.; Zhu, S. Z.; Shao, M. Tetrahedron 2008, 64, 5728–5735; (d)
Li, D. M.; Song, L. P.; Li, X. F.; Xing, C. H.; Peng, W. M.; Zhu, S. Z. Eur. J. Org. Chem.
2007, 3520–3525; (e) Li, D. M.; Song, L. P.; Song, S. D.; Zhu, S. Z. J. Fluorine Chem.
2007, 128, 952–957; (f) Li, X. F.; Song, L. P.; Xing, C. H.; Zhao, J. W.; Zhu, S. Z.
Tetrahedron 2006, 62, 2255–2263.
Table 3
Dehydration reaction of 5 to compound 616,17
O
O
NH
OH
NH
11. Typical experimental procedure for synthesis of 5a: A mixture of ethyl-4,4,4-
trifluoro-1,3-dioxobutanoate 3 (1.0 mmol, 184.0 mg), corresponding aromatic
aldehyde 1a (1.0 mmol, 106.0 mg), Meldrum’s acid 2 (1.0 mmol, 144.0 mg),
and ammonium acetate 4 (1.2 mmol, 94.0 mg) in acetic acid (8.0 mL) was
heated at 118 °C for 6 h. After the evaporation of AcOH under reduced pressure,
saturated aqueous NaHCO3 solution and EtOAc were added. The two layers
were separated and the aqueous layer was further extracted with EtOAc. The
combined organic layers were dried over Na2SO4, filtered, and concentrated
under reduced pressure to give a residue, which was purified by column
chromatography on silica gel using petroleum ether/ethyl acetate, 10:1(v/v) as
eluent to give the pure product 5a 221.0 mg, 67% yield.
CF3
CO2Et
CF3
CO2Et
R
R
5
6
Entry
R
Product
Time (h)
Yieldb (%)
1
2
3
H
4-O2N
2-Cl
6a
6b
6c
5
3
3
81
89
85
aReaction conditions: 5 (0.5 mmol), p-TsOH (1.5 mmol, 3 equiv), solvent: CHCl3
12. Spectroscopic data for products 5: Compound 5a: White solid; mp: 169–170 °C;
(8 ml), refluxing.
IR (KBr)
m
max: 3448, 3212, 3110, 2983, 1734, 1691, 1496, 1377, 1201, 1028, 769,
;
b
Isolated yields.
703 cmÀ1
1H NMR (500 MHz, CDCl3): d = 0.77 (t, J = 7.0 Hz, 3H), 2.71 (dd,
J1 = 18.0 Hz, J2 = 12.5 Hz, 1H), 2.82 (dd, J1 = 18.0 Hz, J2 = 5.0 Hz, 1H), 3.18 (d,
J = 12.5 Hz, 1H), 3.62 (ddd, J1 = J2 = 12.5 Hz, J3 = 5.0 Hz, 1H), 3.81 (q, J = 7.0 Hz,
2H), 6.08 (s, 1H), 6.39 (s, 1H), 7.22–7.24 (m, 2H), 7.29–7.37 (m, 3H). 19F NMR
(470 MHz, CDCl3): d = À84.38 (s, 3F, CF3); MS (ESI) m/z: 332 [M+H]+; Anal.
Calcd for C15H16F3NO4: C, 54.38; H, 4.87; N, 4.23. Found: C, 54.13; H, 4.87; N,
4.13.
biological activity. Further studies on the synthetic application of
this method are now in progress.
Acknowledgments
13. CCDC-765386 contains the supplementary crystallographic data for this paper.
These data can be obtained free of charge from The Cambridge Crystallographic
14. Zhu, S. Z.; Song, L. P.; Jin, G. F.; Dai, B. F.; Hao, J. Curr. Org. Chem. 2009, 13, 1015–
1027.
The authors thank the National Natural Science Foundation of
China (NNSFC) (Nos. 20672072, 20772080), Leading Academic Dis-
cipline Project of Shanghai Municipal Education Commission (No.
J50102), the Key Laboratory of Organofluorine Chemistry, Shanghai
Institute of Organic Chemistry, and the Innovation Fund of Shang-
hai University for financial support.
ˇ
ˇ
15. (a) Svetlik, J.; Goljer, I.; Turecek, F. J. Chem. Soc., Perkin. I 1990, 1315–1318; (b)
Ochoa, E.; Suárez, M.; Verdecia, Y.; Pita, B.; Martin, N.; Quinteiro, M.; Seoane,
C.; Soto, J. L.; Duque, J.; Pomés, R. Tetrahedron 1998, 54, 12409–12420; (c)
Rodriguez, H.; Suarez, Z.; Pérez, R.; Petit, A.; Loupy, A. Tetrahedron Lett. 2003,
44, 3709–3712.
16. Typical experimental procedure for preparation of 6a: A solution of compounds 5
(0.5 mmol, 165.5 mg) and p-TsOH (1.5 mmol, 3.0 equiv, 285.0 mg) in CHCl3
(8.0 mL) was refluxed (62 °C) for indicated hours until completion of the
reaction (monitored by TLC). The solvent was removed by rotavapor and the
residue was purified by column chromatography on silica gel using petroleum
ether/ethyl acetate 8:1 (v/v) as eluent to afford the pure product 6a 253.0 mg,
81% yield.
References and notes
1. (a) Hiyama, T. Organofluorine Compounds; Springer: Berlin, 2000; (b) Hudlicky,
M. Chemistry of Organic Fluorine Compounds, 2nd ed.; Ellis Harwood: Chichester,
1976.
2. (a)Fluorine in Bioorganic chemistry; Welch, J. T., Eswarakrishnan, S., Eds.; Wiley:
New York, 1991; (b) Prabhakaran, J.; Underwood, M. D.; Parsey, R. V.; Arango,
V.; Majo, V. J.; Simpson, N. R.; Heertum, R. V.; Mann, J. J.; Kumar, J. S. D. Bioorg.
Med. Chem. 2007, 15, 1802–1807.
3. (a) Filler, R.; Kobayashi, Y. Biomedicinal Aspects of Fluorine Chemistry; Kodansha
& Elsevier Biomedical: Tokyo, 1982; (b) Filler, R.; Kobayashi, Y.; Yagupolskii, L.
M. Organofluorine Compounds in Medical Chemistry and Boimedical Application;
Elsevier: Amsterdam, 1993.
17. Spectroscopic data for products 6: Compound 6a: White solid; mp: 145–146 °C;
IR (KBr)
m
max: 3224, 3135, 2993, 1720, 1689, 1598, 1484, 1368, 1217, 1013,
786, 772, 748 cmÀ1
;
1H NMR (500 MHz, CDCl3): d = 1.16 (t, J = 7.0 Hz, 3H), 2.80
(dd, J1 = 17.0 Hz, J2 = 4.5 Hz, 1H), 2.96 (dd, J1 = 17.0 Hz, J2 = 7.5 Hz, 1H), 4.12 (q,
J = 7.0 Hz, 2H), 4.22–4.26 (m, 1H), 7.19–7.21 (m, 2H), 7.26–7.29 (m, 1H), 7.31–
7.34 (m, 2H), 7.74 (s, 1H). 19F NMR (470 MHz, CDCl3): d = À64.27 (s, 3F, CF3);
MS (ESI) m/z: 336 [M+Na]+; Anal. Calcd for C15H14F3NO3: C, 57.51; H, 4.50; N,
4.47. Found: C, 57.72; H, 4.49; N, 4.36.